Seasonal influenza virus vaccine quadrivalent - sanofi pasteur

Drug Profile

Seasonal influenza virus vaccine quadrivalent - sanofi pasteur

Alternative Names: Fluzone QIV ID; Fluzone QIV IM; Fluzone Quadrivalent; Fluzone Quadrivalent vaccine; QIV; Quadrivalent inactivated influenza virus vaccine; Quadrivalent influenza vaccine; Vaxigrip QIV IM; VaxigripTetra

Latest Information Update: 08 Mar 2017

Price : $50

At a glance

  • Originator sanofi pasteur
  • Developer Sanofi Pasteur
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 02 Jan 2017 Sanofi Pasteur MSD ended their joint venture and will separately pursue their vaccine strategies in Europe
  • 01 Jul 2016 Sanofi Pasteur completes a phase-III trial in Influenza virus infections (In adults, Prevention) in South Korea (IM) (NCT02550197)
  • 23 Jun 2016 German Reference Member State Paul Ehrlich Institute issues a positive end of procedure as a conclusion of the European Decentralised procedure for Influenza virus infections (Prevention, In children, In adolescents, In adults) (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top